Przemyslaw Grygier (Przemysław Grygier)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Tyrosine Kinase

Inflammatory Response

Capillary Electrophoresis

Top Venues

Journal of medicinal chemistry

ACS chemical neuroscience

This page only lists publications with an associated author ORCID identifier.

Publications

Izabella Góral, Tomasz Wichur, Emilia Sługocka, Przemyslaw Grygier, Monika Głuch-Lutwin, Barbara Mordyl, Ewelina Honkisz-Orzechowska, Natalia Szałaj, Justyna Godyń, Dawid Panek, Paula Zaręba, Anna Sarka, Paweł Żmudzki, Gniewomir Latacz, Katarzyna Pustelny, Adam Bucki, Anna Czarna, Filipe Menezes, Anna Więckowska
Exploring Novel GSK-3β Inhibitors for Anti-Neuroinflammatory and Neuroprotective Effects: Synthesis, Crystallography, Computational Analysis, and Biological Evaluation. ACS chemical neuroscience (2024)
Przemyslaw Grygier, Katarzyna Pustelny, Jakub Nowak, Przemyslaw Golik, Grzegorz M Popowicz, Oliver Plettenburg, Grzegorz Dubin, Filipe Menezes, Anna Czarna
Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective. Journal of medicinal chemistry 66 (6) (2023)
Przemyslaw Grygier, Katarzyna Pustelny, Jakub Nowak, Przemyslaw Golik, Grzegorz M Popowicz, Oliver Plettenburg, Grzegorz Dubin, Filipe Menezes, Anna Czarna
Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective. Journal of medicinal chemistry (2023)
Przemyslaw Grygier, Katarzyna Pustelny, Jakub Nowak, Przemyslaw Golik, Grzegorz M Popowicz, Oliver Plettenburg, Grzegorz Dubin, Filipe Menezes, Anna Czarna
Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective. Journal of medicinal chemistry 66 (6) (2023)